Created at	Source	Raw Value	Validated value
April 13, 2024, 8 a.m.	usa	Phase 2/3, PK: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) for Bebtelovimab [Arm 23];Phase 2: Change From Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Phase 2: Percentage of Participants Who Experience a Serious Adverse Event(s) SAE(s);Phase 3 and Phase 2/3 [Arm 22], Pharmacokinetics (PK): Mean Concentrations of LY3819253 (Bamlanivimab);Phase 3 and Phase 2/3 [Arm 22], Pharmacokinetics (PK): Mean Concentrations of LY3832479 (Etesevimab);Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo Groups;Phase 3: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo	Phase 2/3, PK: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) for Bebtelovimab [Arm 23];Phase 2: Change From Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Phase 2: Percentage of Participants Who Experience a Serious Adverse Event(s) SAE(s);Phase 3 and Phase 2/3 [Arm 22], Pharmacokinetics (PK): Mean Concentrations of LY3819253 (Bamlanivimab);Phase 3 and Phase 2/3 [Arm 22], Pharmacokinetics (PK): Mean Concentrations of LY3832479 (Etesevimab);Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo Groups;Phase 3: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo
March 8, 2022, 10:30 p.m.	usa	Phase 2: Change From Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Phase 2: Percentage of Participants Who Experience a Serious Adverse Event(s) SAE(s);Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo Groups;Phase 3: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo	Phase 2: Change From Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Phase 2: Percentage of Participants Who Experience a Serious Adverse Event(s) SAE(s);Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg Bamlanivimab/1400mg Etesevimab and Their Placebo Groups;Phase 3: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo
March 31, 2021, 12:31 a.m.	usa	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants who Experience a Serious Adverse Event(s) SAE(s);Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold;Pharmacokinetics (PK): Area Under the Concentration-time Curve from 0 to Infinity (AUC0-inf) for both LY3819253 and LY3832479	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants who Experience a Serious Adverse Event(s) SAE(s);Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold;Pharmacokinetics (PK): Area Under the Concentration-time Curve from 0 to Infinity (AUC0-inf) for both LY3819253 and LY3832479
March 18, 2021, 12:31 a.m.	usa	4. Pharmacokinetics (PK): Area Under the Concentration-time Curve from 0 to Infinity (AUC0-inf) for both LY3819253 and LY3832479;5. Percentage of Participants who Experience a Serious Adverse Event(s) SAE(s);Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold	4. Pharmacokinetics (PK): Area Under the Concentration-time Curve from 0 to Infinity (AUC0-inf) for both LY3819253 and LY3832479;5. Percentage of Participants who Experience a Serious Adverse Event(s) SAE(s);Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Jan. 29, 2021, 12:31 a.m.	usa	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Nov. 11, 2020, 11:31 p.m.	usa	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold	Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load;Percentage of Participants Who Experience COVID-Related Hospitalization or Death;Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Oct. 26, 2020, 11:31 p.m.	usa	Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold;Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load	Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold;Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load